ATOS Atossa Therapeutics

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Individuals interested in viewing the live presentation can register for the free event here: . A video replay of the presentation will be available for 90 days following the event on the investor relations page of Atossa’s website: and on Channelchek: . 

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit

Contact

Eric Van Zanten

VP, Investor and Public Relations

610-529-6219



EN
11/04/2024

Underlying

ATOSAtossa Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Atossa Therapeutics

 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, ...

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,281,056) directed to highly pure and stable enteric oral formulations comprising (Z)-endoxifen as well as therapeu...

April 30, 2025 1 EN
 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at...

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today outlined a framework for a pioneering Phase 3 clinical study titled SMART 2.0. The proposed trial would investigate the potential of oral (Z)-endoxifen, a potent Selective Estrogen Receptor Modulator (SERM) for estrogen receptor inhibition, to si...

April 29, 2025 1 EN
 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, ...

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,275,684) directed to enteric oral formulations comprising (Z)-endoxifen as well as methods of treating subjects with those oral formulations. This new...

April 22, 2025 1 EN
 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Therapeutics Announces Full Year 2024 Financial Results and Pro...

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company develop...

March 25, 2025 1 EN
 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financ...

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-ye...

March 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch